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Summary. Chronic respiratory otorhinolaryngological (ORL) diseases may exacerbate. Broncalt® is a class II 
Medical Device containing: thermal water (Medesano, PR, Italy), hyaluronic acid, and grapefruit seed extract. 
It could exert a safe and effective anti-inflammatory, washing, and antimicrobial activity. The current survey, 
conducted in clinical practice of 84 Italian ORL centers, evaluated its safety and efficacy in the treatment of 
patients with exacerbated chronic upper airways disease. The 459 (254 males, mean age 44.7 years) patients 
were evaluated at baseline (T0) and after a 2-week treatment (T1), treated or not-treated with Broncalt®. 
Signs and symptoms severity were measured by visual analogue scale. Broncalt® significantly, quickly, and 
safely diminished the clinical features in all sub-groups (p<0.001 for all). In conclusion, Broncalt® is a class 
II Medical Device able to exert a safe, quick, and effective activity in patients with relapsed chronic ORL 
disorders. (www.actabiomedica.it)
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O r i g i n a l  a r t i c l e
Introduction
Airways disorders are very common in clinical 
otorhinolaryngological (ORL) practice. Chronic up-
per airways diseases may relapse usually because of 
infections.
Respiratory exacerbations may be commonly 
caused by bacterial, viral or fungal aetiology, even 
though non-infectious cause might also be implied. 
However, infection is the most frequent reason for 
exacerbated chronic ORL disease. The treatment of 
relapsed chronic airways diseases is targeted to fight 
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both infection and inflammation using antibiotics and 
anti-inflammatory drugs. Pharmacological therapy 
is usually effective, but there is increasing interest to 
consider complementary medicine as alternative op-
tion (1-3).
In this regard, Broncalt® is a new class II medical 
device containing salso-bromo-iodine thermal water 
(spring of Medesano, PR, Italy) 8%, hyaluronic acid 
(HA) 0.1%, and grapefruit seed extract 0.35%.
Recently, it has been reported that Broncalt® was 
effective in the treatment of postnasal drip-related 
cough in children with upper respiratory tract infec-
tions (4).
On the basis of this background, an Italian survey 
explored the pragmatic approach of a group of oto-
laryngologists in the management of relapsed chronic 
upper-airways disorders in clinical practice. Therefore, 
the aim of the current survey was to evaluate the effi-
cacy and safety of Broncalt® in outpatients with exac-
erbated chronic respiratory ORL diseases.
Materials and Methods
The current survey was conducted in 84 Italian 
ORL centers, distributed in the whole Italy, so assur-
ing a wide and complete national coverage. Otolaryn-
gologists were asked to recruit all consecutive patients 
visited because of exacerbated chronic ORL disease.
Patients were consecutively recruited during the 
specialist visit. The inclusion criteria were: to have a di-
agnosis of relapse of chronic ORL disease, both genders, 
and adulthood. Exclusion criteria were to have comor-
bidities and concomitant medications able to interfere 
the evaluation of outcomes. As this survey was based on 
a real-world practice, the doctors had the complete lib-
erty of choosing the preferred medications on the basis 
of the best practice. Actually, patients were subdivided 
in 2 sub-groups: i) patients treated with standard thera-
py plus Broncalt® (active group), and ii) patients treated 
with standard therapy alone (control group).
All patients signed an informed consent. All the 
procedures were conducted in a real-world setting.
The treatment course lasted 2 weeks. The medi-
cal device Broncalt® (Aurora Biofarma, Milan, Italy) 
was taken following the specific indications, such as 
two tablets/daily. Patients were visited at baseline (T0), 
after 1-week treatment (T1), and after 2-week treat-
ment (T2).
Clinical examination and fiber-endoscopy were 
evaluated in all patients at all visits. 
All clinical data were inserted in an internet-plat-
form that guaranteed the patients’ anonymity and the 
findings’ recording accuracy. 
The following clinical parameters were evaluated: 
nasal obstruction, mucosal edema, hyperemia, ear-
ache, swelling, sore throat, dysphagia, dysphonia, and 
cough. These issues were considered both as the quote 
of patients having them and their perceived severity. 
Symptom severity was assessed by a visual analogue 
scale (VAS). VAS is a psychometric test widely used to 
measure the patient’s perception of symptom severity, 
emotions, pain, etc. Currently, VAS is a reliable and val-
id tool to assess the perception of symptoms and signs 
(16). The VAS consisted of one ruler asking for signs 
and symptoms severity perception. In this study, the 
VAS was a 10-cm horizontal line on which 0 implied 
the absence of sing or symptom, while 10 corresponded 
to maximal severity. VAS is considered a routine and 
validated parameter to assess disease severity in clinical 
practice and inflammatory markers are closely related 
with nasal obstruction perception (17). 
In addition, the symptom disappearance duration 
was also considered, such as 3 period were established 
for symptom receding: by 3 days, between 4-7 days, 
and beyond 7 days.
Doctors also evaluated: the effectiveness (scored 
as very effective, effective, scarcely effective, and in-
effective), the tolerability (scored as very good, quite 
good, poorly good, no good), and the compliance (very 
good, good, scarcely good, and no good).
Safety was measured by reporting the occurrence 
of adverse events.
The paired T-test was used. Statistical significance 
was set at p <0.05. Data are expressed as medians and 
1th and 3rd quartiles. The analysis was performed using 
STATA, College Station, Texas, USA. 
Results
Globally, 459 (254 males, mean age 44.7 years) 
patients were visited and completed the treatment 
course. 
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The demographic characteristics and type of 
chronic respiratory disease are reported in Table 1.
In particular, the two subgroups were similar con-
cerning the gender and the age.
The distribution of chronic relapsed respiratory 
diseases was significantly different about some types, 
i.e. patients not-treated with Broncalt had more fre-
quently recurrent otitis an chronic tonsillitis, whereas 
Broncalt-treated patients suffered more commonly 
from chronic pharyngitis. Subgroup treated with 
Broncalt took significantly less antibiotics, but more 
anti-inflammatory drugs than the other subgroup; in-
terestingly Broncalt-treated subgroups did not take 
any medication more frequently (51% versus 6.3%).
Considering the frequency of patients without 
symptoms or signs after the treatment, Broncalt treat-
ment induced higher percentages of symptomless pa-
tients for nasal obstruction, rhinorrhea, dysphonia, and 
edema (Table 2). 
The percentages of patients treated with or with-
out Broncalt with global symptom disappearance 
within 3 days, and over 7 days were significantly differ-
ent between groups (Figure 1). In particular, 44.7% of 
Broncalt-treated patients and 14.3% of patients with-
out Broncalt treatment had no more symptoms within 
3 days (p=0.007). On the contrary, 27% of patients 
without Broncalt treatment and 66.7% of Broncalt-
treated patients still present symptoms over one week 
(p<0.001).
In patients treated with Broncalt, the perception 
of efficacy was very good in 74.2% and good in 21.2% 
(Figure 2A); the tolerability was very good in 83.7% 
and good in 15.2% (Figure 2B); the compliance was 
very good in 82.6% and good in 16.3% (Figure 2C).
The treatment was well tolerated by all patients 
and no relevant adverse event was reported.
Table 1. Demographic and clinical characteristics of patients, treated with or without Borncalt
 Broncalt No Broncalt p-value
 N=396 N=63
Characteristic
Male gender, n(%) 223 56.3% 31 49.2% 0.292
Mean age, (SD) 44.5 22.2 45.5 19.2 0.960
Relapsed disease      
Recurrent Otitis, n(%) 74  18.7% 8 12.7% 0.249
Chronic Tonsillitis, n(%) 17 4.3% 9 14.3% 0.001
Chronic Laryngitis, n(%) 40 10.1% 5 7.9% 0.592
Chronic Rhinopharyngitis, n(%) 112 28.3% 14 22.2% 0.317
Chronic Pharyngitis, n(%) 74 18.7% 13 20.6% 0.714
Dysphonia, n(%) 51 12.9% 8 12.7% 0.968
Concomitant treatments 
Antibiotics 26 6.6% 5 7.9% 
     Cefalosporins 13 3.3% 3 4.8% 
     Chinolones 4 1.0% 0 0% 
     Macrolides 3 0.8% 0 0% 
     Other 6 1.5% 2 1.1% 
Anti-inflammatory 115 29.0% 23 3.2% 
     Antipyretics 3 0.8% 0 0% 
     Corticosteroids 95 24.0% 18 28.6% 
     FANS 10 1.3% 4 6.3% 
     Other 7 2.5% 1 1.6% 
Anti-inflammatory+antibiotics 53 13.4% 31 49.2% 
No drug 202 51.0% 4 6.3% 
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Figure 1. Percentages of patients treated with or without Bron-
calt with symptom disappearance within 3 days, between 3 and 
7 days, and over 7 days.
Table 2. Proportion of patients without symptoms and signs 
after treatment in the two subgroups: treated with or without 
Broncalt, evaluated at T1
Symptom Broncalt No Broncalt  P
Facial pain 21.2% 11.1% 0.062
Nasal Obstruction 51.8% 31.8% 0.003
Rhinorrea 39.7% 22.2% 0.008
Post nasal drip  30.8% 25.4% 0.384
Earache 21.7% 15.9% 0.289
Nose swelling 34.9% 30.2% 0.466
Sore thorat 23.7% 27.0% 0.576
Dysphonia 25.8% 14.3% 0.048
Cough 39.4% 27.0% 0.059
Hyperaemia 59.1% 47.6% 0.087
Edema 41.2% 20.6% 0.002
Figure 2. A= Patients’ perception of Broncalt efficacy; B= Patients’ perception of Broncalt tolerability; C= Patients’ perception of 
Broncalt Compliance.
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Discussion
The current survey demonstrated that Broncalt® 
significantly improved the clinical feature in relapsed 
chronic upper airways disorders in ORL clinical prac-
tice. In particular, the clinical effectiveness of Broncalt 
was quick as about 50% of treated patients achieved a 
symptom disappearance just within 3 days. Notably, 
patients in Broncalt subgroup more frequently did not 
assume any medication. The present findings are con-
sistent with a previous study that explored the thera-
peutic effects of this medical device in the treatment of 
children with ORL infections (4). 
The use of non-pharmacological treatment rep-
resents a challenging option. The present survey sup-
ports the concept that complementary medicine may 
have a role in clinical practice also in patients with 
respiratory exacerbation. In fact, previous systematic 
reviews evidenced that herbal medicines could be ben-
eficial in the treatment of rhinosinusitis and othe ORL 
disorders (1-3). Therefore, the present survey confirms 
that a medical device, such as Broncalt®, may signifi-
cantly reduce clinical features in chronic ORL disor-
ders characterized by an exacerbation. 
However, the current experience has some limita-
tions, mainly concerning the open design and the lack 
of objective functional data. On the other hand, the 
strength of this survey is the high number of enrolled 
patients and the real-world setting, so the findings may 
mirror what occurs in the daily practice.
In conclusion, the present survey evidenced that 
Broncalt® may induce a safe and quick control of 
respiratory complaints in inflammatory exacerbated 
chronic ORL disorders.
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